Haleon plc: Completion of acquisition of remaining 12% in China JV

27 June 2025: Haleon plc (the "Company" or "Haleon") today announces that it has completed the acquisition announced on 15 April 2025, of the remaining 12% equity interest in Tianjin TSKF Pharmaceutical Co. Ltd ("TSKF"), its OTC joint venture in China for a total consideration of RMB 1,623 million (c. £0.2 billion). As a result, TSKF is now a wholly owned subsidiary of Haleon.

China is a key market for Haleon which is underpinned by favourable structural drivers. The acquisition of TSKF which has a long heritage of operational excellence will enable Haleon to drive category growth in one of the fastest growing OTC markets globally. TSKF accounted for c. 40% of Haleon's China revenues in 2024 and manufactures and/or distributes leading brands such as Fenbid, Voltaren and Bactroban. This acquisition will deliver increased strategic, and operational flexibility, and is fully consistent with our capital allocation priorities to drive attractive returns for shareholders and maintain a strong investment grade balance sheet.

Enquiries

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com.